TiumBio’s Post

Nurix Therapeutics' ($NRIX) BTK degrader has a theoretical advantage in treating CLL with resistance mutations to BTK small molecule inhibitors. 📜 The authors report a novel finding of on-target mutations that impair enzymatic activity but instead allow BTK to act as a scaffold and continue to drive BCR signalling. NX-2127 gets around the scaffolding issue by degrading BTK. https://lnkd.in/dAKvZyaT

CelluSPOT Synthese im Peptidsynthesizer MultiPep 2 Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers https://lnkd.in/euSWUk8p #Peptode #peptide #peptidsynthesizer #peptidesynthesis #CelluSPOT #Multipep #CEM #Intavis  

CelluSPOT Synthese im Peptidsynthesizer MultiPep 2 Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers https://lnkd.in/eGFnuFwJ #Peptode #peptide #peptidsynthesizer #peptidesynthesis #CelluSPOT #Multipep #CEM #Intavis

CelluSPOT Synthese im Peptidsynthesizer MultiPep 2 Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers https://lnkd.in/eGFnuFwJ #Peptode #peptide #peptidsynthesizer #peptidesynthesis #CelluSPOT #Multipep #CEM #Intavis #medikamente

I am excited to share our recent publication demonstrating that Fc-active anti-TIGIT therapeutics can deplete NK cells via fratricide. Therapies targeting TIGIT have so far underperformed in clinics, particularly anti-TIGIT that can engage antibody-dependent cell cytotoxicity (Fc-active). NK cells are a critical population for the efficacy of anti-TIGIT therapeutics, and our prior work demonstrated that activated NK cells overexpress TIGIT, correlating with better anti-tumor function (https://lnkd.in/ewr3TJsn).  Therefore, the depletion of NK cells by Fc-active anti-TIGIT candidates may contribute to their failure. Here, we showed that knocking out TIGIT prevents fratricide, enhances NK cell cytotoxicity, and improves their metabolism. Thus, co-administration with TIGIT KO NK cells may offer a potential solution to improve the effectiveness of anti-TIGIT therapies.  This work was led by a talented graduate student in my laboratory Md Faqrul Hasan and a postdoctoral fellow Tayler Croom-Perez.  I am also grateful for the wonderful collaboration and contributions of my long-time collaborator, Dr. Dean Lee, and his group. Well done, team! #TIGIT, #NK cells, #immunotherapy

Source: Therapeutic drug monitoring A method was developed to simultaneously detect ibrutinib, dihydroxydiol ibrutinib (DHI), and zanubrutinib in human plasma using liquid chromatography-mass spectrometry/mass spectrometry. The method involved protein precipitation and chromatographic separation, with analytes separated within 6.5 minutes. The method was validated and used to analyze plasma concentrations of these drugs in patients with certain types of lymphoma. The patients were between 44 and 74 years old. PMID: 38531816 | DOI: 10.1097/FTD.0000000000001190

This paper suggests that a novel CEACAM6-targeted antibody–drug conjugate (ADC) named EBET for PDAC therapy. CEACAM6-EBET ADC delivers BET protein degrader via CEACAM6 antibody, Modulation of PDAC Stromal : Bystander efficacy on CEACAM6-negative Cancer-Associated Fibroblasts (CAFs) inhibits STAT3 signaling, contributing to break down of the PDAC stromal. Authors say that this dual impact on PDAC cells and stroma is a key feature. https://lnkd.in/g43BaqPm

Antibody drug conjugates (ADCs) are fast-growing fields and attract strong interests from antibody professionals. We are highlighting selected ADCs papers published on Antibody Therapeutics (current CiteScoreTracker: 8.3), the official journal of Chinese Antibody Society. The 9th paper was entitled “Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine/cysteine conjugation” contributed by William Roush and Christoph Rader from The Scripps Research Institute. https://lnkd.in/gqjfA2W We also highly recommend the special Issue Collection: Antibody-targeted Cytotoxic agents – Immunotoxins and ADCs. This special issue collection includes 14 excellent review and research articles. Special thanks to the two guests, Dr. Antonella Antignani and Dr. David FitzGerald at National Cancer Institute (NCI) of The National Institutes of Health. You may find more ADCs collection through https://lnkd.in/e76efmRZ We are also welcoming new submission for "Antibody-Drug Conjugates for Cancer Treatment" through https://lnkd.in/eU87q8zn #ADCs #Antibody #Therapeutics #Immunotoxins

Overcoming BTK mutations that confer resistance across covalent and noncovalent BTK inhibitors. Disrupting the scaffold function of BTK by NX-2127, a potent BTK degrader, a drug that could degrade both wild-type and mutant forms of the BTK protein. In a phase 1 clinical trial, NX-2127 showed promising responses for patients with relapsed and refractory CLL, independently of mutant BTK functional category and may provide a means of treating those tumors resistant to current BTK inhibitors.

All About Antibody Drug Conjugates… What makes this new type of cancer treatment a game-changer for cancer patients? In this clip from our LIVE “Office Hours” Zoom call with cancer specialist Alex Rolland and advocacy expert Michelle Morand, Alex explains why a new type of cancer treatment – called Antibody Drug Conjugates – are a game-changer for many patients. He also shares how cancer patients can find out if the treatment can work for them…and, if so, how to access it fast, and for as little cost as possible. Watch here 👉https://buff.ly/3VD4znw 👀 These live Zoom calls happen each Wednesday as a part of our free Cancer Care Advocacy & Education Support Group, called “Cancer: Just the Facts” 👉 Join Cancer Just the Facts (free) and get access to a variety of resources on Precision Cancer Medicine as well as access to our weekly Zoom calls: https://buff.ly/3TAAS5a #HopeIsHere #PrecisionCancerMedicine